Loading company…
Paw Therapeutics uses AI and cross-species data to develop anti-aging drugs for pets and people.
Founded in 2025 in Shenzhen, Paw Therapeutics researches anti-aging drugs for pets and humans using AI models and biological data. The company aims to apply data from pet clinical trials to human drug programs and uses AI for target discovery and antibody optimization. In May 2026, it closed an angel round led by Monolith Management.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in